Clinical Trials Directory

Trials / Completed

CompletedNCT04142125

Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease

Combination Anti-thrombotic Treatment for Prevention of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease: Protocol for a Pilot Randomized Trial

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
101 (actual)
Sponsor
Population Health Research Institute · Academic / Other
Sex
All
Age
40 Years
Healthy volunteers
Not accepted

Summary

CATIS-ICAD is a clinical pilot study in which patients who have had a recent ischemic stroke, that is a stroke caused by a blood clot or a narrowing of the blood vessels in the brain due to the build up of plaque, will be randomly assigned to receive either low-dose rivaroxaban + aspirin or aspirin alone.

Conditions

Interventions

TypeNameDescription
DRUGRivaroxaban 2.5 Mg Oral Tablet bidPts will receive rivaroxaban + aspirin
DRUGAcetylsalicyclic acid 81 mg tablet qdPts will receive ASA

Timeline

Start date
2020-02-03
Primary completion
2023-09-18
Completion
2023-09-18
First posted
2019-10-29
Last updated
2023-09-26

Locations

10 sites across 1 country: Canada

Source: ClinicalTrials.gov record NCT04142125. Inclusion in this directory is not an endorsement.

Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease (NCT04142125) · Clinical Trials Directory